Abstract. The efficacy of fluconazole was evaluated in 35 travelers with parasitologically proven imported Old World cutaneous leishmaniasis (CL). Leishmania major (mainly MON-25) was identified in 15 patients and strongly suspected given the transmission area in 12 of these patients. Daily oral fluconazole (200 mg/day for adults and 2.5 mg/kg/day for children) was prescribed for six weeks. Outcome definition was based on re-epithelialization rate at day 50. Of the 27 L. major-infected patients, 12 (44.4%) were cured. This cure rate is similar to the placebo cure rate from trials in L. major CL in which, as in the present report, the definition of outcome relied exclusively on re-epithelialization. These data question the assumption that oral fluconazole is consistently effective for treatment of CL caused by L. major.
INTRODUCTION
A sharp increase in the worldwide incidence of cutaneous leishmaniasis (CL) has been observed over the last 10 years (from 1 million to 1.5 million new cases per year), 1 which has likely increased the number of imported CL cases throughout Europe. For example, 123 cases of imported or autochtonous CL were reported to the French National Reference Center of Leishmania in 2004, which was four times higher than the mean of 30-31 cases per year that had been reported over a two-year period in 1986-1987. 2 Leishmania major from North Africa and south Saharan Africa is more frequently involved with CL than L. infantum and L. tropica (500/C/ BanqueLeishmania/BLRapportActivité2001). Most Old World CL lesions heal spontaneously over months to years, and mean time to healing is typically shorter in those caused by L. major than those caused by L. infantum or L. tropica. 3 Abstention is a theoretically attractive option; however, it is more easily adopted when writing recommendations than when facing a patient. Many clinicians would favor therapy because lesions are often disfiguring, may affect daily occupation and/or social life when located on the hands, feet, or face, and frequently give rise to atrophic scars. However, reference therapeutic options such as pentavalent antimonial drugs may be more harmful than the disease. 4 Severe adverse events rarely occur in young patients in clinical trials, 5, 6 but these events may be more frequent in older patients treated without follow-up of laboratory parameters and electrocardiograms. 7 Thus, search for safe and easily administered therapies is a priority.
In this context, oral fluconazole proved more efficient than placebo in an L. major focus in Saudi Arabia. 8 Because comparative trials in CL caused by L. major had previously shown the inefficiency of either intramuscular 9 or intralesional 10 pentavalent antimonial drugs, oral fluconazole became the best substantiated therapeutic option. 11 A standardized follow-up procedure is applied to all patients with CL in our clinics. This provided the framework to assess the efficacy of oral fluconazole in patients returning from different Old World areas with one or several CL lesions. Patients received fluconazole at a dosage of 200 mg/day for six weeks for adults and 2.5 mg/kg/day for six weeks for children. Patients of all ages and independent of the number or location of their lesions were prescribed fluconazole. The data of this patients were analyzed whenever they fulfilled the following criteria: CL parasitologically confirmed by smear and/or culture and/or PCR, with objective measurement of the lesions at day 1 and direct objective measurement of the lesions or measurement on dated photographs at day 50 ± 8, and if clinical follow-up over the telephone was performed later than day 90.
MATERIALS AND METHODS

Patients
The infecting species was either identified or strongly suspected on the basis of epidemiologic criteria. For example, strong suspicion of L. major infection meant that patients traveled exclusively to a L. major focus according to reference tables (World Health Organization Technical Report on Leishmaniasis Control, 1990) and maps (http://www.Edisan .fr). Most patients were born in northern and Sahelian Africa, had lived in Europe, and had spent weeks to months in their city of origin during the Leishmania transmission season. Be-cause L. major, L. infantum, and L. tropica foci rarely overlap in Africa, we suspected more than one potential infecting species only in a few patients (Tables 1 and 2 ). Outcome was defined as 1) complete clinical response: 100% reepithelialization of all lesions at day 50 ± 8 or Ն 50% reepitheliazation of all lesions at day 50 ± 8 with 100% reepithelialization of all lesions at day 90 ± 8, or 2) clinical failure: < 50% re-epithelialization of at least one lesion at day 50 ± 8 or < 100% re-epithelialization of at least one lesion at day 90 ± 8.
Determination of drug toxicity. At the beginning (day 0), middle (days [14] [15] [16] [17] [18] [19] [20] [21] , and end of treatment (days 42-55), we checked for symptoms suggesting possible drug side effects, i.e., gastrointestinal, neurologic, cutaneous, and any unusual symptom experienced by the patient since the last consultation. Laboratory tests to monitor liver enzymes (aspartate (Tables 1 and 2 ). Data from 10 patients were not included in the analysis for the following reasons: one had a purely nodular lesion, one had received previous antimonial drug therapy less than 10 days before taking fluconazole, one did not purchase fluconazole because of cost, and seven did not return for follow-up and/or did have photographs taken at day 50 ± 8, which made objective measurement impossible.
Except for two patients infected with L. tropica, four with L. infantum, and two for which more than one species could be responsible for the lesion ( Figure 1 ). Of eight patients infected with non-L. major or undetermined species (two L. tropica, four L. infantum, and two undetermined), three were cured. However, only four patients in this second group had completed a full course of therapy (Table 2) . Two patients complained of nausea and abdominal pain and one patient reported a mild and clinically insignificant increase in the level of aspartate aminotransferase (59 U/L, normal ‫ס‬ 14-50 U/L). In one patient, treatment was interrupted because of toxicity (severe nausea). This patient was lost for follow-up and was not included in the efficacy analysis.
DISCUSSION
Oral fluconazole administered to Saudi patients infected with L. major MON-26 8 was associated with a cure rate of 36% at seven weeks (day 9) compared with 10% in placebotreated patients. At 13 weeks (day 91), results of fluconazole were still superior to those of placebo (88% versus 66%, percentages from Figure 1 in the report by Alraghi and others 8 ). Compared with previous reports, those cure rates are low. The placebo cure rate in this Saudi trial (6% at day 42 and 10% at day 49) 8 is the lowest reported for treatment of CL caused by L. major. 8, 9, [13] [14] [15] [16] [17] [18] Other studies performed in L. major foci reported cure rates in the placebo group at days 45-50 of 17%, 18 18-32%, 13 22.8%, 14 44%, 15 44.3%, 16 53%, 17 and 55%. 9 . We recently conducted a phase II study in L. major (mainly MON-25)-infected patients that included a placebo group, in which the day 50 cure rate was 71%.
In our group of 27 fluconazole-treated patients with proven or suspected L. major MON-25 or MON-74 CL acquired in northern or Sahelian Africa, and with an evaluable outcome, the cure rate at day 50 was 44.4% (Table 1 and Figure 1 ). Although this cure rate is similar to the fluconazole cure rate of 36% at day 49 in Saudi Arabia, it is similar to the 44% and 44.3% placebo cure rates at days 45-50 observed in trials using a re-epithelialization-based criterion. We find it more relevant to compare our results with those analyzed according to an equivalent criterion. 15, 16 Among factors that may explain the wide range of spontaneous cure rates in the previously published trials, the criterion used to determine lesion outcome is probably an important one. Objective criteria based exclusively on ulceration size (or its antonym, the percentage of re-epithelialization), 15, 16 were associated with higher cure rates than subjective criterions taking in account more than one characteristic of lesions, 8, 18 an observation consistent with the fact that the disappearance of the induration or inflammation of a lesion usually occurs several weeks after its re-epithelialization. 16 In one trial, induration size was explicitly included in the outcome definition. 18 The placebo cure rate was 17%. 18 Cure in the Saudi trial was defined as complete healing of all lesions. 8 Complete healing was not further defined but likely took into account not only re-epithelialization but also lesion induration, color, or both. Thus, a lesion that would have been reported as still active during the trial performed in Saudi Arabia might have been considered cured in other studies, including the present report. If interpreted following the criterion used in Saudi Arabia, the cure rate in our fluconazole-treated patients group would have been lower (because outcome was not objectively defined by Alrajhi and others 8 we could not use their criterion). Seven patients were excluded from the analysis because they were lost to follow-up. If we assume that all seven excluded patients were cured, the cure rate is 55.9%; if all seven patients were not cured, the cure rate is 35.3%. Both values are still close to placebo cure rates from several previous trials. Our patients presented latter in the evolution than patients in Saudi Arabia (3.7 versus 1.9 months, Table 1 and Alrajhi and others   8 ), thus increasing the likelihood of spontaneous healing in our cohort. These observations favor the hypothesis that spontaneous evolution was the predominant factor of lesion healing in the present report.
The L. major species is not homogenous. At least 16 L. major zymodemes (MON 3, 4 Zymodemes might be associated with distinctive and unique natural evolutions. Also, in CL, the infecting species has a proven influence on therapeutic outcome. 21 No report on the influence of zymodemes is available, but discrepancies on the efficacy of meglumine antimoniate and allopurinol on CL caused by L. panamensis in Colombia have been reported. [22] [23] [24] Although these data are from New World foci, they support the hypothesis that zymodeme-dependent drug efficacy might induce cure rate dis-crepancies between patients infected with the same species but who were infected in different geographic areas (e.g., Middle East versus Africa). Clinical trials including a large proportion of L. major MON 25-infected patients are necessary.
Although our data were not generated by a formal clinical trial, they deserve clinical attention. These data question the widespread assumption, due to the prominence of the previous report from Saudi Arabia, 8 that oral fluconazole is consistently effective for treatment of CL caused by L. major. Even for patients in northern countries, a six-week course of fluconazole is expensive. 25 Almost 15% of our patients could not afford a full course of fluconazole because of the high cost (at least 600 Euros for a full course in France). Definitive evidence is required before recommending fluconazole in the treatment of imported Old World CL.
